Sentynl Therapeutics has secured an option for US commercial rights to alvelestat, a potential first oral treatment for a rare genetic lung disease affecting up to 80,000 Americans.
Sentynl Therapeutics has secured an option for US commercial rights to alvelestat, a potential first oral treatment for a rare genetic lung disease affecting up to 80,000 Americans.